Pfizer (PFE)
(Delayed Data from NYSE)
$28.94 USD
-0.15 (-0.52%)
Updated Sep 30, 2024 04:00 PM ET
After-Market: $28.91 -0.03 (-0.10%) 7:26 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$28.94 USD
-0.15 (-0.52%)
Updated Sep 30, 2024 04:00 PM ET
After-Market: $28.91 -0.03 (-0.10%) 7:26 PM ET
2-Buy of 5 2
B Value F Growth D Momentum D VGM
Zacks News
Myovant (MYOV), Pfizer sNDA for Myfembree Accepted by the FDA
by Zacks Equity Research
Myovant's (MYOV) application for the label expansion of Myfembree gets accepted by the FDA for the indication of pain associated with endometriosis.
Pharma Stock Roundup: SNY to Buy Kadmon, New Approvals for AZN & MRK's Drugs
by Kinjel Shah
Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business. AstraZeneca's (AZN) Ultomiris and Merck's (MRK) Keytruda get approvals for expanded use.
Should Principal U.S. MegaCap ETF (USMC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for USMC
Erasca (ERAS) Inks Deal With Pfizer for Colorectal Cancer Study
by Zacks Equity Research
Erasca (ERAS) signs an agreement with Pfizer for a clinical study, which will evaluate ERAS-007 in combination with encorafenib and cetuximab for BRAF V600E-mutant metastatic colorectal cancer.
Novavax (NVAX) Begins Clinical Study on COVID/Flu Combo Jab
by Zacks Equity Research
Novavax (NVAX) starts enrolling patients in a phase I/II study to evaluate a combination of its COVID vaccine and seasonal influenza vaccine.
Pfizer (PFE) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed at $46.51 in the latest trading session, marking a -0.51% move from the prior day.
Tap the Nasdaq Rally With These Two Leveraged ETFs
by Sweta Killa
Investors could easily tap the bullish trend by considering a near-term long on the Nasdaq Index with the help of ETFs.
Ascendis (ASND) Seeks FDA Nod for New Immunotherapy Study
by Zacks Equity Research
Ascendis (ASND) plans to develop a sustained-release immunotherapy to treat advanced cancer developed using its TransCon platform.
Merck's (MRK) Keytruda Gets Nod for Expanded Use in China
by Zacks Equity Research
Merck's (MRK) Keytruda gets approval in combination with chemotherapy in the first-line setting for advanced esophageal and GEJ cancer in China based on data from the phase III KEYNOTE-590 study.
Moderna (MRNA) Inks Deal to Develop Ultra-Rare Disease Therapy
by Zacks Equity Research
Moderna (MRNA) inks a collaboration deal with the Institute for Life Changing Medicines to develop a free of charge mRNA-based therapy to treat Crigler-Najjar Syndrome type 1, an ultra-rare disease.
Zacks Industry Outlook Highlights: Johnson & Johnson, Roche, Pfizer and AstraZeneca
by Zacks Equity Research
Zacks Industry Outlook Highlights: Johnson & Johnson, Roche, Pfizer and AstraZeneca
4 Big Drugmaker Stocks to Watch Out For as Recovery Gains Steam
by Kinjel Shah
Most Large Cap Pharmaceuticals industry players' Q2 results were strong. Regulatory/pipeline updates related to COVID-19 medicines/vaccines continue to take center stage. JNJ, RHHBY, PFE and AZN are worth retaining in your portfolio.
Moderna (MRNA) Seeks Authorization for Booster Dose in Europe
by Zacks Equity Research
Moderna (MRNA) is developing a booster dose of its COVID-19 vaccine, mRNA-1273, for enhancing protection against infection in individuals.
Celsion (CLSN) COVID Vaccine Effective in Pre-Clinical Studies
by Zacks Equity Research
Celsion (CLSN) announces data from pre-clinical studies for its investigational vaccine platform as a potential treatment for COVID-19.
Adamis (ADMP) Begins Dosing in COVID Oral Antiviral Study
by Zacks Equity Research
Adamis (ADMP) starts dosing patients in phase II/III study to evaluate its oral investigational antiviral for the treatment of COVID-19.
Pharma Stock Roundup: New Warning Order by FDA for JAK Drugs, & Pipeline Updates
by Kinjel Shah
FDA requires a heart-risk warning on the label of JAK inhibitor medicines, Pfizer's (PFE) Xeljanz, Lilly's (LLY) Olumiant, and AbbVie's (ABBV) Rinvoq. Sanofi, Merck and others give pipeline updates.
5 Niche ETFs Sizzling This Summer
by Sweta Killa
Wall Street has been shining bright this summer thanks to upbeat corporate earnings, renewed optimism in a sustained economic recovery, and the Fed's dovish view.
Pfizer (PFE) Begins Study on RSV Vaccine in Older Adults
by Zacks Equity Research
Pfizer (PFE) starts a phase III study which will evaluate its respiratory syncytial virus vaccine candidate, RSVpreF in adults aged 60 years and above.
5 Top-Ranked ETFs That Outperformed in August
by Sweta Jaiswal, FRM
Let's take a look at some top-ranked ETFs that outperformed Wall Street in August.
Merck (MRK) Begins Molnupiravir Study for COVID Prevention
by Zacks Equity Research
Merck (MRK) starts enrolling participants in phase III study to evaluate its oral investigational antiviral for the prevention of COVID-19.
AbbVie (ABBV) Stock Down as FDA Issues New Warning for Rinvoq
by Zacks Equity Research
FDA requires a heart-risk warning on the label of AbbVie's (ABBV) JAK inhibitor medicine, Rinvoq.
4 Small-Cap ETFs & Stocks to Explode Higher
by Sweta Killa
With renewed optimism over a sustained economic recovery and robust corporate earnings growth, the small-cap space is set to explode higher.
Moderna (MRNA) Gives First COVID Jab Booster Data to the FDA
by Zacks Equity Research
Moderna's (MRNA) booster dose of COVID-19 vaccine elicits antibody levels that were much higher than that seen after the two-dose primary schedule.
5 Tech Stocks Leading the Latest Nasdaq ETF Rally
by Sweta Killa
Most of the rally was powered by renewed buying in the high-growth tech giants as tapering fears ease as well as optimism over a sustained economic recovery.
FDA Orders Warnings on Pfizer, Lilly, AbbVie JAK Drug Labels
by Kinjel Shah
The FDA requires a heart-risk warning on the label of JAK inhibitor medicines, Pfizer's (PFE) Xeljanz/Xeljanz XR, Lilly (LLY)/Incyte's (INCY) Olumiant, and AbbVie's (ABBV) Rinvoq.